Institutional investment to pursue strategic initiatives
Filed with ASX · · 4 pages · English
Summary by 6ix AI
The investment comprises contributions from New Life Sciences Capital LLC and the Meurs Group, providing AdAlta with financial flexibility for its ongoing projects. The funds will primarily be used to accelerate progress on a recently announced partnership with SYNthesis BioVentures and to advance internal i-body programs.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
In the deck
Earlier from AdAlta
- SYNBV MoU Webinar presentation
- SYNThesis BioVentures MoU for cellular immunotherapies
- Corporate Presentation
- Positive AD-214 Phase I extension study results
- January 2024 partnering presentations and progress
Later from AdAlta
- Extension of Victorian Government RDTI Loan Facility
- Cellular immunotherapy manufacturer secured - Cell Therapies
- $1.9 million raised from exercise of 1ADOA options
- Transaction, investment facility update
- FY24 RDTI Refund Received $1.77m
Follow AdAlta into a list and get an email when it puts out news.
Follow AdAlta